Further advances revealed promising TGF-β’s downstream targets or modulators of signaling (e.g., Smad7, Smad3-dependent noncoding RNA) to therapeutically target CKD [35,36,37]; however, none has emerged so far in the clinic. The gene discussed is SMAD3; the disease is chronic kidney disease.